JUN 29·SEC EDGARLow
Lynx1 Capital Management LP purchased $206K of PASG (indirect holdings)
Lynx1 Capital Management LP purchased 50,055 indirectly-held shares of Passage BIO, Inc. (PASG) at $4.12 ($0.21M total) on 2026-06-25.
StockNASDAQ · US · USDHealthcare · Biotechnology
$PASG
Passage BIO, Inc.
Price · $PASGvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $PASG in the last 7 days.
Insider · 30dAll trades →
No SEC Form 4 filings for $PASG in the last 30 days.
See all $PASG insider activity →Top stories · $PASGMore →
JUN 24·SEC EDGAR 8-K
Passage BIO, Inc. (PASG): Entry into a Material Definitive Agreement
Passage BIO, Inc. (PASG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 tm2618476d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: PASSAGE BIO, INC.; PEREGRINE MERGER SUB, INC.; and REMIX THERAPEUTICS, INC. Dated as of June 24, 2026 TABLE OF CONTENTS Page Article I DEFINITIONS AND INTERPRETATIVE PROVISIONS 3 1.1
MAR 31·Investing.com
Oppenheimer initiates Passage Bio stock with outperform rating
Oppenheimer has initiated coverage of Passage Bio Inc. (NASDAQ:PASG) with an outperform rating and a price target of $30.00, suggesting a significant upside of 385% from its current price. The firm believes the stock's 46% year-to-date decline is an overreaction to competitor program failures and regulatory concerns, presenting a buying opportunity. Oppenheimer highlighted key differentiators for Passage Bio's lead asset PBFT02 in frontotemporal dementia, projecting $1 billion in peak risk-adjusted sales by 2040.
PASG sentiment & insider activity
Recent PASG coverage spans financial news, insider activity and corporate actions.
What's driving PASG
A 10% owner’s open-market indirect purchase is a modest, sentiment-oriented signal but not a fundamental catalyst by itself.
Deal announcement via 8-K increases takeover/merger probability and sets up near-term catalysts (proxy/stockholder vote, regulatory approvals, closing conditions).
Oppenheimer's initiation of coverage with an outperform rating and a $30 target suggests strong upside potential for Passage Bio, driven by undervaluation after a 46% decline this year.
Passage Bio reports positive clinical trial progress and financial results, indicating potential growth. The company's focus on neurodegenerative disease therapies aligns with current biotech sector trends.
Analysts' consensus suggests a potential 731% upside for Passage Bio (PASG), driven by strong earnings estimate revisions despite limited historical effectiveness of such metrics.
alphai scores every news story that mentions PASG with an AI model for sentiment and relevance, and aggregates insider trades from Passage BIO, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $PASG
Score
Lynx1 Capital Management LP purchased $206K of PASG (indirect holdings)
Lynx1 Capital Management LP purchased 50,055 indirectly-held shares of Passage BIO, Inc. (PASG) at $4.12 ($0.21M total) on 2026-06-25.
2 min readPassage BIO, Inc. (PASG): Entry into a Material Definitive Agreement
Passage BIO, Inc. (PASG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 tm2618476d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: PASSAGE BIO, INC.; PEREGRINE MERGER SUB, INC.; and REMIX THERAPEUTICS, INC. Dated as of June 24, 2026 TABLE OF CONTENTS Page Article I DEFINITIONS AND INTERPRETATIVE PROVISIONS 3 1.1
4 min read
Oppenheimer initiates Passage Bio stock with outperform rating
Oppenheimer has initiated coverage of Passage Bio Inc. (NASDAQ:PASG) with an outperform rating and a price target of $30.00, suggesting a significant upside of 385% from its current price. The firm believes the stock's 46% year-to-date decline is an overreaction to competitor program failures and regulatory concerns, presenting a buying opportunity. Oppenheimer highlighted key differentiators for Passage Bio's lead asset PBFT02 in frontotemporal dementia, projecting $1 billion in peak risk-adjusted sales by 2040.
3 min readPassage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
Actively enrolling Cohort 3 ( FTD-GRN ) and Cohort 4 ( FTD-C9orf72 ) patients in ongoing upliFT-D study ...
3 min read
Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet
The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4 min read
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference - Passage Bio (NASDAQ:PASG)
PHILADELPHIA, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Passage Bio, Inc. PASG, a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C.
3 min readPassage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
PHILADELPHIA, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Passage Bio, Inc. ( NASDAQ: PASG ) , a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C.
2 min read
Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade
The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4 min read